health pharma news today obesity drugs glp-1 A new oral option is now part of medicine. FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight with at least one weight-related The Global Obesity Therapeutics Market:

Among 69,221 propensity-matched patients with IBD, those who had received a GLP-1 RA had a 5-year colorectal cancer incidence of 0.2% compared with 0.42% in non-GLP-1 RA users (OR, 0.49), corresponding to a 51% reduction in odds of developing colorectal cancer

beta-Caryophyllene suppresses ferroptosis induced by cerebral ischemia reperfusion via activation of the NRF2/HO-1 signaling pathway in MCAO/R rats

Lancet, 397(10286), 17361748

Gently massage into the skin until the capsules fully dissolve

Both types of melanin showed activity against the DPPH and ABTS radicals, but the level of this protection was much lower than in the case of vitamin C